DINAMIC SCREENING OF PRECANCEROUS ESOPHAGUS USING MOLECULAR GENETIC ANALYSIS

Introduction. Esophageal adenocarcinoma develops from areas of intestinal metaplasia in Barrett’s esophagus, similar to how intestinal metaplasia transforms into gastric adenocarcinomas in the stomach. Atypia with intraepithelial neoplasia is difficult to distinguish from reactive and regenerative changes, especially in erosive mucosa of the esophagus. Observation of patients with Barrett’s esophagus allows the identification of adenocarcinoma in the earlier, more curable stages in many patients.

The aim of our study was to study the prospects of using a classifier based on miRNA profiling in histological samples of Barrett’s esophagus to determine the risk of malignancy and treatment tactics.

Material and Methods. In this study, 119 samples of archival histological material in the form of paraffin blocks were used: 89 samples of gastric mucosa with dysplasia and 30 samples of Barrett’s esophagus. The expression level of miRNA-145-5p, -150-5p, -20a-5p, -21-5p,-31-5p,-34a-5p,-375 was determined using real-time RT-PC R. Samples were stratified into different groups using the C-RT decision tree algorithm.

Results. 26.7 % of Barrett’s esophagus samples were classified by expression of the proposed miRNAs as cancer, which may indicate a potential development of a malignant tumor in the mucosa of the esophagus when morphological changes have not yet been found.

1. Wani S., Drahos J., Cook M.B., Rastogi A., Bansal A., Yen R., Sharma P., Das A. Comparison of endoscopic therapies and surgical resection in patients with early esophageal cancer: a population-based study. Gastrointest Endosc. 2014 Feb; 79(2): 224–232.e1. doi: 10.1016/j.gie.2013.08.002.

2. Pech O., May A., Manner H., Behrens A., Pohl J., Weferling M., Hartmann U., Manner N., Huijsmans J., Gossner L., Rabenstein T., Vieth M., Stolte M., Ell C. Long-term efficacy and safety of endoscopic resection for patients with mucosal adenocarcinoma of the esophagus. Gastroenterology. 2014 Mar; 146(3): 652–660.e1. doi: 10.1053/j.gastro.2013.11.006.

3. Fitzgerald R.C., di Pietro M., Ragunath K., Ang Y., Kang J.Y., Watson P., Trudgill N., Patel .P, Kaye P.V., Sanders S., O'Donovan M., Bird-Lieberman E., Bhandari P., Jankowski J.A., Attwood S., Parsons S.L., Loft D., Lagergren J., Moayyedi P., Lyratzopoulos G., de Caestecker J.; British Society of Gastroenterology. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett’s oesophagus. Gut. 2014 Jan; 63(1): 7–42. doi: 10.1136/gutjnl-2013-305372.

4. Corley D.A., Mehtani K., Quesenberry C., Zhao W., de Boer J., Weiss N.S. Impact of endoscopic surveillance on mortality from Barrett’s esophagus-associated esophageal adenocarcinomas. Gastroenterology. 2013 Aug; 145(2): 312–9.e1. doi: 10.1053/j.gastro.2013.05.004.

5. Qiao Y., Hyder A., Bae S.J., Zarin W., O'Neill T.J., Marcon N.E., Stein L., Thein H.H. Surveillance in Patients With Barrett’s Esophagus for Early Detection of Esophageal Adenocarcinoma: A Systematic Review and Meta-Analysis. Clin Transl Gastroenterol. 2015 Dec 10; 6(12): e131. doi: 10.1038/ctg.2015.58.

6. Vennalaganti P., Kanakadandi V., Goldblum J.R., Mathur S.C., Patil D.T., Offerhaus G.J., Meijer S.L., Vieth M., Odze R.D., Shreyas S., Parasa S., Gupta N., Repici A., Bansal A., Mohammad T., Sharma P. Discordance Among Pathologists in the United States and Europe in Diagnosis of Low-Grade Dysplasia for Patients With Barrett’s Esophagus. Gastroenterology. 2017 Feb; 152(3): 564–570.e4. doi: 10.1053/j.gastro.2016.10.041.

7. Di Leva G., Garofalo M., Croce C.M. MicroRNAs in cancer. Annu Rev Pathol. 2014; 9: 287–314. doi: 10.1146/annurevpathol-012513-104715.

8. Pereira A.L., Magalhães L., Moreira F.C., Reis-das-Mercês L., Vidal A.F., Ribeiro-Dos-Santos A.M., Demachki S., Anaissi A.K.M., Burbano R.M.R., Albuquerque P., Dos Santos S.E.B., de Assumpção P.P., Ribeiro-Dos-Santos Â.K.C. Epigenetic Field Cancerization in Gastric Cancer: microRNAs as Promising Biomarkers. J Cancer. 2019 Feb 26; 10(6): 1560–1569. doi: 10.7150/jca.27457.

9. Hwang J., Min B.H., Jang J., Kang S.Y., Bae H., Jang S.S., Kim J.I., Kim K.M. MicroRNA Expression Profiles in Gastric Carcinogenesis. Sci Rep. 2018 Sep 26; 8(1): 14393. doi: 10.1038/s41598-018-32782-8.

10. Titov S.E., Ivanov M.K., Karpinskaya E.V., Tsivlikova E.V., Shevchenko S.P., Veryaskina Y.A., Akhmerova L.G., Poloz T.L., Klimova O.A., Gulyaeva L.F., Zhimulev I.F., Kolesnikov N.N. miRNA profiling, detection of BRAF V600E mutation and RET-PTC1 translocation in patients from Novosibirsk oblast (Russia) with different types of thyroid tumors. BMC Cancer. 2016 Mar 9; 16: 201. doi: 10.1186/s12885-016-2240-2.

11. Titov S.E., Anishchenko V.V., Poloz T.L., Veryaskina Yu.A., Arkhipova A.A., Ustinov S.N . Differential Diagnostics of Gastric Cancer and Precancerous Changes of the Gastric Mucosa Using Analysis of Expression of Six Micrornas. Klinicheskaya Laboratornaya Diagnostika. 2020; 65(2): 131–136. (in Russian). doi: 10.18821/0869-2084-2020-65-2-131-136.

12. Krzywinski M., Altman N.S. Classification and regression trees. Nature Methods. 2017; 14(8): 757–758. doi: 10.1038/nmeth.4370.

13. American Gastroenterological Association, Spechler S.J., Sharma P., Souza R.F., Inadomi J.M., Shaheen N.J. American Gastroenterological Association medical position statement on the management of Barrett’s esophagus. Gastroenterology. 2011; 140(3): 1084–91. doi: 10.1053/j.gastro.2011.01.030.

14. Kastelein F., van Olphen S.H., Steyerberg E.W., Spaander M.C., Bruno M.J.; ProBar-Study Group. Impact of surveillance for Barrett’s oesophagus on tumour stage and survival of patients with neoplastic progression. Gut. 2016 Apr; 65(4): 54854. doi: 10.1136/gutjnl-2014-308802.

15. Levine D.S., Blount P.L., Rudolph R.E., Reid B.J. Safety of a systematic endoscopic biopsy protocol in patients with Barrett’s esophagus. Am J Gastroenterol. 2000; 95(5): 1152–7. doi: 10.1111/j.1572-0241.2000.02002.x.

16. Grady W.M., Yu M. Molecular Evolution of Metaplasia to Adenocarcinoma in the Esophagus. Dig Dis Sci. 2018 Aug; 63(8): 2059–69. doi: 10.1007/s10620-018-5090-8.

17. Contino G., Vaughan T.L., Whiteman D., Fitzgerald R.C. The Evolving Genomic Landscape of Barrett’s Esophagus and Esophageal Adenocarcinoma. Gastroenterology. 2017; 153(3): 657–3.e1. doi: 10.1053/j.gastro.2017.07.007.

18. Haidry R.J., Dunn J.M., Butt M.A., Burnell M.G., Gupta A., Green S., Miah H., Smart H.L., Bhandari P., Smith L.A., Willert R., Fullarton G., Morris J., Di Pietro M., Gordon C., Penman I., Barr H., Patel P., Boger P., Kapoor N., Mahon B., Hoare J., Narayanasamy R., O'Toole D., Cheong E., Direkze N.C., Ang Y., Novelli M., Banks M.R., Lovat L.B. Radiofrequency ablation and endoscopic mucosal resection for dysplastic barrett’s esophagus and early esophageal adenocarcinoma: outcomes of the UK National Halo RFA Registry. Gastroenterology. 2013 Jul; 145(1): 87–95. doi: 10.1053/j.gastro.2013.03.045.

19. Phoa K.N., van Vilsteren F.G., Weusten B.L., Bisschops R., Schoon E.J., Ragunath K., Fullarton G., Di Pietro M., Ravi N., Visser M., Offerhaus G.J., Seldenrijk C.A., Meijer S.L., ten Kate F.J., Tijssen J.G., Bergman J.J. Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasia: a randomized clinical trial. JAMA. 2014 Mar 26; 311(12): 1209–17. doi: 10.1001/jama.2014.2511.